News

Gregg Majewski: Transforming Craveworthy, Winning Awards

Gregg Majewski: Transforming Craveworthy, Winning Awards

Award-Winning Visionary Behind Craveworthy Brands

Every so often, someone shakes up the industry with a bold move. Enter Gregg Majewski, the driving force behind Craveworthy Brands, and now crowned the EY US Entrepreneur Of The Year® 2026 Midwest winner. This guy’s been in the restaurant trenches for over 30 years, proving that hustle pays off big time.

From Intern to Industry Giant

Majewski's ride began at Jimmy John's, where he rose from intern to one of the youngest CEOs, CFOs, and COOs. His leadership helped catapult the brand from 30 locations to over 300. Talk about a sandwich empire, right? But he didn’t stop there.

In late 2022, Majewski gambled big on his brainchild, Craveworthy. This multi-brand platform started with a simple premise: nurture emerging concepts with tight systems, and breathe fresh life into legacy brands without stripping them of their essence.

Building on Solid Fundamentals

Fast-forward a few years, and Craveworthy boasts over 20 brands and 300-plus locations, bringing in a jaw-dropping $300 million in systemwide sales. With names like Shaq's Big Chicken and Gregorys Coffee in the mix, it's a smorgasbord of culinary ventures.

"This recognition belongs to our team," Majewski said. "Craveworthy was a dream that's now a booming empire.”

The company approaches growth with a keen eye on sustainability, leaning on 'people, product, and process'. Majewski measures success not just by sales, but by transformations—from dishwashers to managers. It's a people-centric perspective that’s more than lip service; it’s a business mantra.

Strategic Growth: Beyond the Numbers

The mantra led Craveworthy to invest in its own through programs like Crave University, sculpting leaders from within. Here’s a guy who sees beyond bottom lines—he's nurturing an ecosystem, crafting 100,000 success stories by 2035. Lofty? Sure. But if history’s a guide, he just might pull it off.

The recognition from EY shifts Majewski and Craveworthy into a new spotlight. The entrepreneur award is no small potatoes, crowning leaders who either bootstrap from scratch or crank up innovation to rocket their businesses forward. He’s set to compete nationally now, a testament to his influential spirit in the heartland of America.

EY—Celebrating Entrepreneurial Spirit

For 41 years, the Entrepreneur Of The Year program has spotlighted some serious heavyweights—think Starbucks' Howard Schultz and Noom's Saeju Jeong. Majewski joins these ranks, looking at the nationals in November, and possibly, the world stage come May 2027.

Swinging for the fences? Definitely. But isn't that what being an entrepreneur is all about? Majewski has got the guts to steer Craveworthy through choppy waters. If there's one thing to take away from this, it's that bold bets paired with a heck of a lot of hard work can redefine the playing field.

The Craveworthy Future

As Majewski heads towards further accolades, we're left to wonder: will Craveworthy be his lasting legacy or just another milestone on his horizon? Given his track record, it’s likely just the beginning. He seems poised to keep delivering not just food, but opportunities—fueling both stomachs and aspirations across the board.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading